Literature DB >> 28844628

Revision Total Knee Arthroplasty in Octogenarians: An Analysis of 957 Cases.

Patawut Bovonratwet1, Vineet Tyagi1, Taylor D Ottesen1, Nathaniel T Ondeck1, Lee E Rubin1, Jonathan N Grauer1.   

Abstract

BACKGROUND: The number of octogenarians undergoing revision total knee arthroplasty (TKA) is increasing. However, there has been a lack of studies investigating the perioperative course and safety of revision TKA performed in this potentially vulnerable population in a large patient population. The purpose of this study is to compare complications following revision TKA between octogenarians and 2 younger patient populations (<70 and 70-79 year olds).
METHODS: Patients who underwent revision TKA were identified in the 2005-2015 National Surgical Quality Improvement Program database and stratified into 3 age groups: <70, 70-79, and ≥80 years. Baseline preoperative and intraoperative characteristics were compared between the 3 groups. Propensity score matched comparisons were then performed for 30-day perioperative complications, length of hospital stay, and readmissions.
RESULTS: This study included 6523 (<70 years), 2509 (70-79 years), and 957 octogenarian patients who underwent revision TKA. After propensity matching, statistical analysis revealed only higher rates of blood transfusion and slightly longer length of stay in octogenarians compared to <70 year olds. Similarly, octogenarians had only higher rates of blood transfusion and slightly longer length of stay compared to 70-79 year olds. Notably, there were no differences in mortality or readmission between octogenarians compared to younger populations.
CONCLUSION: These data suggest that revision TKA can safely be considered for octogenarians with the observation of higher rates of blood transfusion and slightly longer length of stay compared to younger populations. Octogenarian patients need not be discouraged from revision TKA solely based on their advanced age.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  American College of Surgeons National Surgical Quality Improvement Program; octogenarian; postoperative adverse events; readmission; revision total knee arthroplasty

Mesh:

Year:  2017        PMID: 28844628     DOI: 10.1016/j.arth.2017.07.032

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  6 in total

1.  Thirty-day morbidity and mortality following revision total shoulder arthroplasty in octogenarians.

Authors:  Puneet Gupta; Theodore Quan; Zachary R Zimmer
Journal:  Shoulder Elbow       Date:  2021-06-26

Review 2.  Patient-Related Risk Factors for Unplanned 30-Day Hospital Readmission Following Primary and Revision Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.

Authors:  Daniel Gould; Michelle M Dowsey; Tim Spelman; Olivia Jo; Wassif Kabir; Jason Trieu; James Bailey; Samantha Bunzli; Peter Choong
Journal:  J Clin Med       Date:  2021-01-02       Impact factor: 4.241

3.  Understanding the 30-day mortality burden after revision total knee arthroplasty.

Authors:  SaTia T Sinclair; Melissa N Orr; Christopher A Rothfusz; Alison K Klika; John P McLaughlin; Nicolas S Piuzzi
Journal:  Arthroplast Today       Date:  2021-10-04

4.  Underweight patients are an often under looked "At risk" population after undergoing posterior cervical spine surgery.

Authors:  Taylor D Ottesen; Paul S Bagi; Rohil Malpani; Anoop R Galivanche; Arya G Varthi; Jonathan N Grauer
Journal:  N Am Spine Soc J       Date:  2020-12-10

5.  Unicompartmental Knee Arthroplasty in Octogenarians: A National Database Analysis Including Over 700 Octogenarians.

Authors:  Harold G Moore; Christopher A Schneble; Joseph B Kahan; Jonathan N Grauer; Lee E Rubin
Journal:  Arthroplast Today       Date:  2022-04-04

6.  Episode-of-Care Costs for Revision Total Joint Arthroplasties by Decadal Age Groups.

Authors:  Christopher Fang; Nicholas Pagani; Matthew Gordon; Carl T Talmo; David A Mattingly; Eric L Smith
Journal:  Geriatrics (Basel)       Date:  2021-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.